Actuate Therapeutics, Inc.
ACTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001652935
No open-market purchases or sales by Actuate Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $20.6M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Actuate Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +6 vs. Q4 2024
- Shares held
- 10.4M
- +285.5K (+2.8%) vs. Q4 2024
- Total value
- $70.4M
- −$10.1M (−12.5%) vs. Q4 2024
- New holders
- 9
- 10 more added
- Sold out
- 3
- 1 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACTU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 62 | $20.6M |
| Q1 2026 | 61 | $38.0M |
| Q4 2025 | 45 | $80.2M |
| Q3 2025 | 43 | $80.5M |
| Q2 2025 | 38 | $68.5M |
| Q1 2025 | 25 | $70.4M |
| Q4 2024 | 19 | $80.5M |
| Q3 2024 | 10 | $2.85M |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Actuate Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 25 | $169 | 0.00% | +1+4.2% | Added |
| Citigroup Inc | 649 | $4.39K | 0.00% | +647+32,350.0% | Added |
| Morgan Stanley | 1,538 | $10.4K | 0.00% | +996+183.8% | Added |
| UBS Group AG | 1,979 | $13.4K | 0.00% | +45+2.3% | Added |
| Tower Research Capital LLC (TRC) | 2,555 | $17.3K | 0.00% | +2,555 | New |
| Northwestern Mutual Wealth Management Co | 3,125 | $21.2K | 0.00% | +3,125 | New |
| BlackRock, Inc. | 7,598 | $51.4K | 0.00% | −147−1.9% | Reduced |
| Freestone Capital Holdings, LLC | 10,000 | $67.7K | 0.00% | 00.0% | Unchanged |
| SFMG, LLC | 11,000 | $74.5K | 0.01% | +11,000 | New |
| KG&L Capital Management,LLC | 12,000 | $81.2K | 0.03% | 00.0% | Unchanged |
| Millennium Management LLC | 12,185 | $82.5K | 0.00% | +12,185 | New |
| Citadel Advisors LLC | 14,185 | $96.0K | 0.00% | +14,185 | New |
| Chicago Partners Investment Group LLC | 10,365 | $96.4K | 0.00% | +10,365 | New |
| Marshall Wace, LLP | 16,114 | $109.1K | 0.00% | +16,114 | New |
| Mercer Global Advisors Inc | 16,344 | $110.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 18,574 | $125.7K | 0.00% | +4,278+29.9% | Added |
| Royal Bank of Canada | 18,538 | $126.0K | 0.00% | +18,236+6,038.4% | Added |
| Goldman Sachs Group Inc | 22,358 | $151.4K | 0.00% | +11,105+98.7% | Added |
| Sigma Planning Corp | 23,675 | $160.3K | 0.01% | +7,600+47.3% | Added |
| Northwestern University | 27,778 | $188.1K | 0.30% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 33,489 | $226.7K | 0.00% | +5,596+20.1% | Added |
| Susquehanna International Group, LLP | 47,634 | $322.5K | 0.00% | +47,634 | New |
| Northern Trust Corp | 53,852 | $364.6K | 0.00% | +53,852 | New |
| Voss Capital, LLC | 142,381 | $963.9K | 0.07% | +87,135+157.7% | Added |
| BIOS Capital Management, LP | 9,893,651 | $67.0M | 84.59% | 00.0% | Unchanged |
| Omers Administration Corp | 0 | $0 | 0.00% | −10,583−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −10,465−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −3−100.0% | Sold out |